The disease
Fatty liver disease may degenerate towards NASH, with three main hallmarks: hepatocyte dysfunction (ballooning), inflammation and fibrosis.
Fatty liver disease may degenerate towards NASH, with three main hallmarks: hepatocyte dysfunction (ballooning), inflammation and fibrosis.
The molecular bases of NASH
Accumulation of fat in the liver is the first and reversible event that occurs within the progression from a healthy liver towards non-alcoholic fatty liver (NAFLD) and then to NASH. The progressive degeneration of the functional liver cells (hepatocytes), due to abnormal handing and accumulation of lipids, leads to activation of liver-resident (Kupffer cells) or infiltrated macrophages in the liver parenchyma, which with time lead to additional damage of hepatocytes. Together this vicious cycle leads to a fibrotic liver, characterized by portal hypertension, and progressive loss of hepatic function. Finally, NASH may degenerate in liver cirrhosis and even lead to hepatocellular carcinoma.
NASH in figures
GlobalData reported about 70M prevalent cases of NASH in the 7 major markets (MM) in 2019. The global NASH market accounted for 174.8M$ in 2021 and it is expected to reach a value of 27$ by 2031 showing a growth trend in the following years with a CAGR of 58%. Major players in these areas have been identified.
Meet the team
Contact us by email to get:
- More info about Servatrix Projects.
- A confidential sample of Servatrix Investment Deck.
- Meeting with our technical team and founders.
